Abbott Laboratories (NYSE:ABT) managed to eke out gains of 0.26% in intraday trade. The share price increased by 0.1 points to $38.5. Till last observation, the net money flow was recorded at a negative $(-2.98) million. The total inflow of $0.56 million in upticks was completely overshadowed by an outflow of $3.54 million in downticks, giving the up/down ratio a value of 0.16. The shares have seen a change of -1.74% in the past week.A block trade occurred in the company shares in which the composite value of the upticks was $0 million and the composite value in downticks was $3.08 million. The resultant up/down ratio for the block exchange was 0. The block trade had a negative money flow of $(-3.08) million.
Currently the company Insiders own 0.26% of Abbott Laboratories shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.63% . Institutional Investors own 70.01% of Abbott Laboratories shares. During last six month period, the net percent change held by insiders has seen a change of -1.31%. On the companys insider trading activities, Yoor Brian B, officer (Senior Vice President and CFO) of Abbott Laboratories, unloaded 565 shares at an average price of $39.49 on June 1, 2016. The total amount of the transaction was worth $22,312, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Abbott Laboratories (NYSE:ABT) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.54 points or 1.41% at $37.86 with 11,108,222 shares getting traded. Post opening the session at $38.32, the shares hit an intraday low of $37.85 and an intraday high of $38.56 and the price was in this range throughout the day. The company has a market cap of $55,622 million and the number of outstanding shares have been calculated to be 1,469,152,000 shares. The 52-week high of Abbott Laboratories (NYSE:ABT) is $51.74 and the 52-week low is $36.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Piper Jaffray downgrades its rating on Abbott Laboratories (NYSE:ABT). The rating major has initiated the coverage with neutral rating on the shares. Earlier, the shares were rated a Overweight by the brokerage firm. The Analysts at Piper Jaffray raises the price target from $68 per share to $82 per share. The rating by the firm was issued on April 28, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.